Hepatitis contagiosa canis (H.c.c.)--2 cases in Austria

Two cases of H.c.c. which occurred in winter 1987 in Vienna are described. Case one was a female Chow-Chow, 8 weeks of age, that died from the peracute form of the disease. The diagnosis was confirmed by histology and direct immunofluorescence. Case two, a 9-month old female Kuvacz, showed clinical signs of the subacute form of H.c.c. She was hospitalized and therapy was successful. The disease was diagnosed by the typical clinical signs and the raise of antibodies in paired serum samples. Etiology, clinical signs and immunology of H.c.c. are discussed.     

Effect of a new pelleting process on the level of contamination of poultry mash by Escherichia coli and Salmonella

The efficacy of a new pelleting process in eliminating naturally occurring Escherichia coli and salmonella from poultry mash was assessed by comparing the microbial load in raw and processed mash. Instead of using steam produced in a boiler, the new process conditioned mash in an Original Vertical Conditioner with steam and other hot gases generated by direct combustion in a Vaporator. E. coli was isolated from 72-100% of samples of raw mash in all trials, and the mean number of colony-forming units of E. coli/g of samples was 6.8 +/- 4.0 X 10(4). Salmonellae (S. senftenberg, S. bredeney, and S. mbandaka) were isolated from 5-10% of samples of raw mash utilized in three of the seven trials. Within limitations of the sampling and analytical tests utilized, the new pelleting process eliminated salmonella from all mash in which the organism was known to be present but eliminated E. coli in only three trials. The process appeared to be 100% effective against both organisms when mash entering the pellet mill from the conditioner had a temperature of 85.7 C and a moisture content of 14.5% and had been retained and treated with steam and hot gases for 4.1 minutes.     

Spontaneous regression of bovine cutaneous leukosis

Biopsies of skin from a 2-year-old heifer with spontaneously regressing dermal leukosis were examined. The heifer was not infected with bovine leukemia virus and was negative for tumor-associated antigens of enzootic bovine lymphosarcoma. By hematological standards for bovine leukemia, the heifer was positive at about 60 days post-occurrence of the disease (POD). At 53 days POD, lymphoblastic neoplastic cells in the dermis reacted with anti-T lymphocyte monoclonal antibody by the avidin biotin peroxidase complex method. The cells had intracytoplasmic clustered dense bodies under electron microscopy. From 53 to 83 days POD, figures of the transepithelial elimination (TE) against neoplastic cells and perivascular infiltration of small lymphocytes were in the dermis. Small lymphocytes reacted with anti-T lymphocyte monoclonal antibody. At necropsy there were no neoplastic lesions; there were flat lymph node-like tissues in the subcutis. Many germinal centers were seen in the lymphatic organs. Blood lymphocytes at 46 days POD were stimulated by phytohemagglutinin-P and concanavalin A. Sera, taken until 75 days POD and at necropsy, showed an inhibitory effect on mitogen-induced blastogenesis of normal bovine lymphocytes. These results suggested the existence of a spontaneous regressive mechanism against neoplastic lesions by TE and tumor immunity.     

Pharmacologic effects and detection methods of methylated analogs of fentanyl in horses

Pharmacologic effects of alpha-methylfentanyl and 3-methylfentanyl, analogs of fentanyl, were investigated in mares. The ability of an 125I-labeled fentanyl radioimmunoassay (125I-RIA) to detect these methylated fentanyl analogs in individual and pooled urine samples from horses was evaluated. Also, the ability of 7 fentanyl antibodies to react with fentanyl and fentanyl derivatives (sufentanil, alfentanil, and carfentanil) was investigated. Mares were studied in a locomotor test to determine the amount of stimulation methylated fentanyl analogs might induce. Two mares each were given alpha-methylfentanyl at 1, 2, 4, 8, or 13 micrograms/kg of body weight, IV, or 3-methylfentanyl at 0.4, 0.7, or 1 microgram/kg IV. The cross-reactivity of sufentanil, alfentanil, carfentanil, alpha-methylfentanyl, and 3-methylfentanyl with 7 fentanyl antibodies was studied, using the 125I-RIA. All fentanyl analogs, with the exception of alfentanil, cross-reacted well with a C1 antibody raised to fentanyl. Less satisfactory cross-reactivity was determined with 6 other antibodies raised to fentanyl derivatives. When the C1 antibody was combined with an iodinated analog to fentanyl, good detectability of alpha-methylfentanyl and 3-methylfentanyl, in terms of fentanyl equivalents, was obtained from urine samples of dosed mares. The ability of the 125I-RIA to detect methylated fentanyl analogs in forensic urine samples pooled in groups of up to 20 samples was evaluated. When these methylated analogs were administered to mares in doses that induced measurable locomotor stimulation, the analog's presence was readily detected in individual or pooled samples.     

Enhancement of tetrathiomolybdate-induced copper excretion in bile of sheep by the alpha 2-agonistic action of xylazine

The effect of intravenous doses of cortisol and xylazine on the quantity of copper excreted in response to 100 and 200 mg doses of tetrathiomolybdate (TTM) was studied in seven sheep. Cortisol alone produced a non-significant 1.4-fold increase and had no enhancing action on the response to TTM. Xylazine produced a significant 2.25-fold increase, doubled the quantity of copper excreted in response to both doses of TTM and reduced bile flow by approximately 35 per cent. The alpha 2 antagonist, idazoxan, prevented both the latter effects showing that they were due to xylazine's alpha 2-agonistic action. It is suggested that the combination of an alpha 2-agonist with the intravenous injection of TTM in the treatment of acute copper toxicity in sheep could reduced by 50 per cent the amount of molybdenum needed.